Form 4: Silence Therapeutics Director and 10% Owner Significantly Increases Stake

Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc, has substantially increased his beneficial ownership through multiple purchases of American Depositary Shares in late June 2025.

Summary

• Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc (SLN), reported multiple purchases of American Depositary Shares (ADSs).
• On June 26, 2025, Griffiths acquired 65,739 ADSs at a price of $5.91 per ADS, and an additional 20,735 ADSs at $5.67 per ADS.
• On June 27, 2025, Griffiths purchased 24,000 ADSs at a price of $5.82 per ADS.
• Each American Depositary Share is immediately convertible into three ordinary shares for no additional consideration and has no expiration date.
• Following these transactions, Richard Ian Griffiths' direct beneficial ownership of Ordinary Shares, represented by ADSs, increased to 11,624,908.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to significant insider buying by a director and 10% owner, indicating strong confidence in the company's prospects.

Positives

• A Director and 10% owner, Richard Ian Griffiths, significantly increased his stake in Silence Therapeutics plc, indicating strong confidence in the company's future prospects.
• The total value of ADSs acquired across the three transactions amounts to approximately $645,740, representing a substantial personal investment by a key insider.
• The purchases were made at varying price points, suggesting a strategic accumulation of shares by a knowledgeable insider.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider buying, particularly by a director and significant owner, is often interpreted by the market as a positive signal, suggesting that those with the most intimate knowledge of the company believe its shares are undervalued or that significant positive developments are anticipated. In the biotechnology and pharmaceutical industry, such signals can be particularly impactful given the long development cycles and binary outcomes of clinical trials.

Stakeholder Impact

• Shareholders may view the significant insider purchases as a strong vote of confidence from a key executive and owner, potentially leading to increased investor interest and positive sentiment towards the stock.

Key Dates

Recommendation

Keywords

Silence Therapeutics, SLN, Form 4, Insider Trading, Director Purchase, ADS, Ordinary Shares, Richard Ian Griffiths, Share Purchase, Beneficial Ownership